A Comparison Between Low Molecular Weight Heparin (KABI 2165) and Standard Heparin in the Intravenous Treatment of Deep Venous Thrombosis

Summary

In order to study whether a low molecular weight heparin (LMWH) of mw 4000 D is effective in the treatment of deep venous thrombosis (DVT), patients with DVT verified by phlebography were randomized to treatment by continuous intravenous infusion of either unfractionated heparin (UFH) or LMWH. The initial dose was 240 U (anti F Xa)/kg/12 h. TTiis study (study I) was stopped because of major bleeding in 2 newly operated patients in the LMWH group after 27 patients had been treated. The heparin activity measured as F Xa inhibition assayed in retrospect, was found to be much higher in the LMWH group (mean 1.6-2.0 anti F Xa U/ml) than in the UFH group (mean 0.5-0.8 anti F Xa U/ml).

A second study was therefore initiated in which the DVT patients were randomly given UFH (240 U/kg/12 h) or LMWH only 120 U (anti F Xa)/kg/12 h, as initial doses (study II). In this study 27 patients could be evaluated, the mean heparin activity still being higher in the LMWH group (0.9-1.2 anti F Xa U/ml) than in the UFH group (0.5-0.7 anti F Xa U/ml).

A second phlebographic investigation showed progression of thrombus size in 3 (11%) of the UFH patients of studies I and II (n = 29) and improvement in 14 (48%). There was no progression in any LMWH patient, 6 (50%) had improved in study I and 10 (77%) in study II. The mean decrease of thrombus size score (according to Marder) during treatment did not differ between the 3 groups.

Antithrombin III decreased significantly in the UFH group but not in the LMWH groups. Aminotransferases increased in all 3 groups. There was no difference in mean capillary bleeding time between the 3 treatment groups.

Although this material is relatively small, our findings suggest that LMWH seems to be of similar effectivity as UFH.

Key words

Thrombosis - Venous - Treatment - Heparin - Low molecular weight heparin - Phlebography

• References

• 1 Holm HA, Finnanger B, Hartmann A, Laerum F, Lohren O, Ruud TE, Stray N, Wolland T. Heparin treatment of deep venous thrombosis in 280 patients: Symptoms related to dosage. Acta Med Scand 1984; 215: 47-53
• 2 Wilson JE, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. Am J Med 1981; 70: 808-816
• 3 Mant MJ, O’Brien BD, Thong KL, Hammond GW, Birthwhistle RV, Grace MG. Haemorrhagic complications of heparin therapy. Lancet 1977; 1: 1133-1135
• 4 Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebog-raphically documented acute deep venous thrombosis. Am J Med 1984; 76: 393-407
• 5 Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy. N Engl J Med 1975; 292: 1046-1050
• 6 Andersson DO, Barrowcliffe TW, Holmer E, Johnsson EA, Sims G EC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
• 7 Holmer E, Kurachi K, Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor XIa, Factor Xlla and Kallikrein by antithrombin. Biochem J 1981; 193: 395-400
• 8 Thomas DP, Merton RE, Lewis WE, Barrowcliffe TW. Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemostas 1981; 45: 214-218
• 9 Cade JF, Buchanan MR, Bonen B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-625
• 10 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of a low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
• 11 Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982; 284: 375-379
• 12 Gouault-Heilmann M, Huet Y, Contand G, Payen D, Block G, Rapin M. Cardiopulmonary bypass with a low-molecular-weight heparin fraction. Lancet 1983; 2: 1374
• 13 Massonnet-Castel S, Pelisson E, Dreyfus G, Deloche A, Abry B, Guibourt P, Terrier E, Passelecq J, Jaulmes B, Carpentier A. Low-molecular-weight heparin in extracorporeal circulation. Lancet 1984; 1182-1183
• 14 Bratt G, Tornebohm E, Lockner D, Bergstrom K. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemostas 1985; 53: 208-211
• 15 Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972; 104: 134-144
• 16 Marder VJ, Soulen RL, Atichartakam V, Budzynski AZ, Parulekar S, Kim JR, Edvard N, Zahavi J, Algazy KM. Quantitative venographic assessment of deep venous thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89: 1018-1029
• 17 King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535-540
• 18 Roussi JH, Honbouyan LL, Gognel AF. Use of low-molecular-weight heparin in the heparin-induced thrombocytopenia with thrombotic complications. Lancet 1984; 1: 1183
• 19 Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Wilhelmsson S. Antithrombin III in patients with acute deep vein thrombosis during heparin treatment (subcutaneous and intravenous) and during and after treatment with oral coumarins. Thromb Res 1984; 34: 333-340